Oncorus Overview
- Year Founded
-
2015

- Status
-
Private
- Employees
-
64

- Latest Deal Type
-
Liquidation
- Investors
-
1
Oncorus General Information
Description
Oncorus Inc is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The company is in the process of developing intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Its pipeline product includes ONCR-021 and ONCR-788 which are based on coxsackievirus A21 or CVA21, and Seneca Valley Virus, or SVV, respectively.
Contact Information
Website
www.oncorus.comCorporate Office
- 4 Corporate Drive
- Andover, MA 01810
- United States
Corporate Office
- 4 Corporate Drive
- Andover, MA 01810
- United States
Oncorus Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
6. Bankruptcy: Liquidation | 01-Jun-2023 | Completed | Bankruptcy: Liquidation | |||
5. 2PO | 12-Feb-2021 | Completed | Generating Revenue | |||
4. IPO | 02-Oct-2020 | Completed | Generating Revenue | |||
3. Early Stage VC (Series B) | 20-Dec-2019 | Completed | Generating Revenue | |||
2. Early Stage VC (Series A2) | 15-Dec-2016 | $23.8M | $61M | Completed | Generating Revenue | |
1. Early Stage VC (Series A1) | 19-Jul-2016 | $37.2M | $37.2M | Completed | Generating Revenue |
Oncorus Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series B | ||||||||
Series A-1 |
Oncorus Comparisons
Industry
Financing
Details
Oncorus Competitors (101)
One of Oncorus’s 101 competitors is Advanced Proteome Therapeutics, a Corporation company based in Boston, MA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Advanced Proteome Therapeutics | Corporation | Boston, MA | ||||
Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
Ikena Oncology | Formerly VC-backed | Boston, MA | ||||
GRI Bio | Formerly VC-backed | La Jolla, CA | ||||
CellCentric | Venture Capital-Backed | Cambridge, United Kingdom |
Oncorus Patents
Oncorus Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20200206285-A1 | Oncolytic viral vectors and uses thereof | Active | 26-Jul-2017 | ||
US-11612625-B2 | Oncolytic viral vectors and uses thereof | Active | 26-Jul-2017 | ||
JP-2023078309-A | Oncolytic virus vector and use thereof | Pending | 26-Jul-2017 | ||
JP-2023165916-A | Encapsulated polynucleotides and methods of use | Pending | 14-Jul-2017 | ||
JP-2022048304-A | Pseudo-oncolytic virus delivery of polypeptide preparation | Inactive | 30-Jun-2016 | C07K16/2818 |
Oncorus Signals
Oncorus Investors (1)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
University of Pittsburgh Innovation Institute | Accelerator/Incubator |
Oncorus ESG
Risk Overview
Risk Rating
Updated May, 21, 2022
26.31 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile

Pharmaceuticals
Industry
of 965
Rank
Percentile

Biotechnology
Subindustry
of 443
Rank
Percentile

Oncorus FAQs
-
When was Oncorus founded?
Oncorus was founded in 2015.
-
Where is Oncorus headquartered?
Oncorus is headquartered in Andover, MA.
-
What is the size of Oncorus?
Oncorus has 64 total employees.
-
What industry is Oncorus in?
Oncorus’s primary industry is Biotechnology.
-
Is Oncorus a private or public company?
Oncorus is a Private company.
-
What is Oncorus’s current revenue?
The current revenue for Oncorus is
. -
How much funding has Oncorus raised over time?
Oncorus has raised $295M.
-
Who are Oncorus’s investors?
University of Pittsburgh Innovation Institute has invested in Oncorus.
-
Who are Oncorus’s competitors?
Advanced Proteome Therapeutics, Adaptimmune Therapeutics, Ikena Oncology, GRI Bio, and CellCentric are some of the 101 competitors of Oncorus.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »